Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see if a specific kind of MRI can identify small and
otherwise undetected abnormal lymph nodes in patients with thyroid cancer who are undergoing
surgery. The MRI is called Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance
Imaging (USPIO MRI), and uses an experimental contrast agent (ferumoxytol), to try to
identify these lymph nodes. The MRI uses magnetic waves to take images (pictures) of the body
and is commonly used in medical testing.
Ferumoxytol is FDA approved as an iron replacement product for the treatment of iron
deficiency anemia in adult patients with chronic kidney disease.
In this research study, the investigators want to see if Ferumoxytol will help to identify
very small metastases that are not usually seen on standard MRI scans. If the use of USPIO
MRI with the experimental agent ferumoxytol identifies very small metastases in lymph nodes,
your surgeon may decide to remove them. After the surgery, the nodes will be stored and then
analyzed to assess the ability of USPIO MRI and ferumoxytol to detect cancer in very small
metastases in the lymph nodes.
Phase:
N/A
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Dextrans Ferric Compounds Ferrosoferric Oxide Iron